Experts discuss PPI use for GI protection in patients on antithrombotics, highlighting risk factors, dosing, drug ...

Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

The improvement of our knowledge on the pharmacodynamics of antiplatelet drugs enables the tailoring of the most appropriate antithrombotic therapy to the individual patient and risk situation in ...

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

Rates of major bleeding and intracranial hemorrhage are similar for apixaban and dabigatran versus aspirin, while rates are ...

A new study has found that the clot-dissolving drug alteplase can significantly improve stroke recovery even when given up to ...

Aims Clopidogrel is the most commonly prescribed thienopyridine as part of dual anti-platelet therapy for the treatment of ...

For some patients with atrial fibrillation (Afib, AF) and valvular heart disease (VHD), direct oral anticoagulants (DOACs) appeared to offer better prevention of stroke and thromboembolic events ...

The clot-dissolving medication, alteplase, improved stroke patients' recovery by more than 50% when given up to 24 hours after the beginning of an ischemic stroke, according to preliminary ...

A recent study from Chinese researchers reveals that alteplase, a clot-busting medication, can significantly improve recovery outcomes for stroke patients, increasing chances of recovery by over 50% ...

A team of Chinese researchers has found that clot-dissolving medication – alteplase – can be key to improving stroke patients ...